Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen. Onivyde, in combination with fluorouracil and leucovorin, was previously approved for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
The designation marks the second Onivyde secured in the past six months. In June, the FDA awarded the designation to Onivyde for patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma.
Ipsen is conducting an ongoing Phase III study assessing Onivyde as a monotherapy for SCLC study patients who have progressed on or after a first-line platinum-based regimen.
Howard Mayer, Ipsens head of research and development, called the Fast Track designation for Onivyde an extension of Ipsens focus and contribution to the oncology landscape.
With this aggressive and often late-stage diagnosed form of lung cancer, we are proud to be one step closer to making another treatment option available to patients, Mayer said in a statement.
Lung cancer is the second most common cancer in the United States. In 2020, the American Cancer Society estimates there to be about 228,280 new cases of lung cancer in the country.SCLC comprises 10% to 15% of all lung cancers and is a very aggressive form of cancer with about 70% of people having metastatic disease when they are diagnosed.
Elsewhere around the globe:
RevoluGen U.K.-based RevoluGen announced new results from its improved Fire Monkey/Fire Flower version 8 (FMv8) protocol. Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of anE. Colibacterial sample on a single Oxford Nanopore Technologies (ONT) MinION flow cell. The increased yield offers significant potential cost and performance advantages across all sequencing platforms, the company said. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. The spin-column has been optimized to deliver homogenous High Molecular Weight DNA extracted and purified from bacterial and mammalian samples. ForE. Coli, the FMv8 protocol allows the ONT MinION to deliver optimal sequencing throughput at an impressive N50 of 36.7Kb, the company added.
GENFIT Frances GENFIT announced the conclusion of the partial buyback of GENFITs 6,081,081 convertible bonds maturing in October 2022. The company said it achieved satisfactory results. Once the buyback is complete, the company will announce the final results.
Abivax Also based in France, Abivax completed recruitment for its Phase IIb induction study for ABX464 as a treatment of patients with moderate-to-severe ulcerative colitis. Top-line results of the PhaseIIbUC induction study are expected to be available in Q2 2021. The Phase IIb induction study in patients with moderate-to-severe UC, enrolled the first patient in August 2019. In addition, Abivax initiated a companion long-term open-label maintenance study in which patients who have completed the induction study were eligible to continue the treatment to further investigate the long-term safety and efficacy profile of ABX464. Previously, the company announced positive results of the previous Phase IIa induction study in UC in September 2018.
HZI Germanys Helmholtz Centre for Infection Research (HZI) secured two awards worth up to $15 million from CARB-X to develop non-traditional approaches against antibiotic-resistant pathogens. The goal is to develop a first-in-class treatment for Staphylococcusaureusinfections and thereby prevent exacerbation of pneumonia. The drug is a small-molecule inhibitor of theS. aureus-hemolysin,a virulence factor responsible for thebacteriums pathogenicity and ability to cause infection and disease. The drug would disarm the pathogens most importanttoxin that causes damage to lung tissue and immune cells. Additionally, HZI is looking to develop a new treatment for difficult-to-treatPseudomonas aeruginosainfections in cystic fibrosis patients. The new pathoblocker treatment aims to disarm pathogens and suppress the disease-causing properties ofP. aeruginosabacteria, instead of killing the bacteria as an antibiotic would aim to do.By rendering the pathogens harmless instead of killing them, selection pressure on the pathogens is relieved and resistance is likely to develop more slowly.
ERS Genomics Irelands ERS Genomics Limited, and Germanys Vivlion GmbH, announced a non-exclusive license agreement granting Vivlionaccess to ERS Genomics CRISPR/Cas9 patent portfolio, to enhance Vivlions gene editing reagents and screening services. Vivlion holds an exclusive license to Goethe University of Frankfurts proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. Financial details of the agreement were not disclosed.
Noema Pharma Swiss startup Noema Pharma secured $59 million in a Series A funding round, as well as four neurological product candidates from Roche. The product candidates will be developed in neurological indications with severe unmet need, such as seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders.
TSK Laboratory Netherlands-based TSK developed a new needle that could save 4% to 8% of vaccine doses, which could prevent wasted parts of the COVID-19 preventative medicines. A conventional needle has an average dead space of 45 microliters, which is the amount of vaccine or medicine being wasted per injection. TSK Laboratory developed an inventive and patented needle in 2014 in which this average dead space is reduced to 14 microliters. TSK said its Low Dead Space technology prevents waste of liquid vaccine when it is being extracted from the container, which will ultimately stretch the number of available doses.
Horizon Discovery Group U.K.-based Horizon Discovery Group granted a license to Chinas Sanyou Biopharmaceuticals Co. for its cGMP-compliant CHOSOURCE platform. Sanyou will use Horizons gene-edited Glutamine Synthetase (GS) knockoutChinese Hamster Ovary(CHO) K1 cell line for the developmentof pre-clinical antibody drug projects andto support the clinical development and commercialization of its customers human biotherapeutic products as well as offering the platform through its contract research services.
eTheRNA Belgium-based eTheRNA immunotherapies NV entered into a strategic agreement with China Grand Pharmaceutical & Healthcare Holdings Ltd. to establish a new joint venture company, Nanjing AuroRNA Biotech Co., Ltd. in Mainland China. The new company will deploy eTheRNAs proprietary mRNA technology for pharmaceutical research and development and production in the Greater China Region. This follows an undisclosed equity investment by China Grand Pharma in eTheRNAs Series B financing round earlier in 2020. The formation of AuroRNA Biotech with China Grand Pharma provides eTheRNA access to the Greater China market for selected mRNA cancer and infectious disease vaccine programs, its proprietary mRNA formulation technologies and GMP manufacturing process technology. eTheRNAs global programs will benefit from China Grand Pharmas development, clinical and marketing input.
4D Biomaterials Innovate UK awarded 4D Biomaterials, a spinout by University of Birmingham Enterprise and Warwick Innovations, to develop new commercialization of a new class of liquid resins that can be custom-printed into bioresorbable 3D tissue scaffolds providing accelerated and improved wound healing following major surgery.
Tubulis Germanys Tubulis formed a strategic collaboration with WuXi STA and WuXi Biologics to manufacture and advance Tubulis next generation antibody-drug conjugates (ADCs) towards IND-enabling studies. Tubulis has developed a dual platform approach to generate uniquely matched and disease-specific ADCs that combine selective antibodies with effective payloads. Tubulisrecently completed a 10.7 million Series A to expand the therapeutic potential of ADCs and to advance itsuniquely versatile and customizable ADC technology portfolio. The company utilizes two proprietary technologies to tacklelimitations of currently approved ADCs, which includestability and payload-driven toxicity.
Most read today on BioSpace:
Visit link:
Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More | BioSpace - BioSpace
- Utilizing your free, preventative healthcare coverage - KELOLAND.com - February 18th, 2024
- Preventive Pros: the Podcast - Department of Population and Public Health Sciences - University of Southern California - February 18th, 2024
- Heart health awareness and preventative care with Jen Lewis on Coast Live - News 3 WTKR Norfolk - February 18th, 2024
- Heart disease risk factors in women highlight need for increased awareness, prevention - American Heart Association - February 18th, 2024
- Preventive health care benefits | Opinion | thecabin.net - Log Cabin Democrat - February 18th, 2024
- Menopause and migraines: New findings point to power of prevention - Medical Xpress - February 18th, 2024
- How Young Is Too Young For Preventative Skincare? Here's What Experts Want You To Know - Health.com - February 18th, 2024
- Potential prevention of rheumatoid arthritis with injection? Clinical study brings hope for millions - WION - February 18th, 2024
- Heart disease risk factors in women highlight need for increased awareness, prevention - Medical Xpress - February 18th, 2024
- Stay on top of your fur baby's health: the importance of scheduling routine vet visits - FoxReno.com - May 17th, 2023
- Preventive healthcare - May 9th, 2023
- What Is Preventive Health and Why Is It Important? - May 9th, 2023
- What Is Preventive Medicine & Why Do We Need It? | AUC - February 16th, 2023
- Preventive Medicine | Journal | ScienceDirect.com by Elsevier - December 3rd, 2022
- Migraine - Diagnosis and treatment - Mayo Clinic - December 3rd, 2022
- Functional Medicine of Idaho | Preventative Root Cause Medicine - December 3rd, 2022
- These 2 Staten Island nurses believe IV hydration drips and vitamin shots are key to long-term health - SILive.com - December 3rd, 2022
- CNBCTV-18 and IIM-K's India@2047 Leadership Series: Challenges and opportunities in the fintech and healthcare sectors - Forbes India - December 3rd, 2022
- As N.W.T. mulls health coverage changes, petition calls for preventative HIV drug to be free - CBC.ca - September 20th, 2022
- EU regulator backs wider use of AstraZeneca COVID therapy - Reuters - September 20th, 2022
- Choose integrative medicine for health and wellness - Technique - September 20th, 2022
- The high hospital bills we make victims of rape and sexual violence pay - Vox.com - September 20th, 2022
- 4 Anti-Aging Products Youre Using All Wrong, According To Skincare Experts - SheFinds - September 20th, 2022
- Why Now is the Time to Double Down on Virtual Care - HIT Consultant - September 20th, 2022
- Tell Giselle: The price of good help is priceless - Wilkes Barre Times-Leader - September 20th, 2022
- Heron Therapeutics Announces U.S. FDA Approval of APONVIE (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) - BioSpace - September 20th, 2022
- Pickleball injuries are on the rise: 5 preventive tips to keep you on the court - The Manual - September 20th, 2022
- The next big social movement and other takeaways from our regular meeting - POLITICO - September 20th, 2022
- 15 Mushrooms and How to Use Them in Vegan Cooking - VegNews - September 20th, 2022
- Use of honey in the management of Chemotherapy | CMAR - Dove Medical Press - September 20th, 2022
- Celebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbes - September 20th, 2022
- C2C Care Course The Preservation of Our Global Photographic Heritage: Here, There and Everywhere - aam-us.org - August 3rd, 2022
- Loneliness: Causes, Effects And Prevention Forbes Health - Forbes - August 3rd, 2022
- Prevention and wellness is the new model, a leader from Henry Ford Health System says - Becker's Hospital Review - August 3rd, 2022
- FACT SHEET: White House Summit on Building Lasting Eviction Prevention Reform - The White House - August 3rd, 2022
- Getting Back to Employer Health and Wellness Programs - Cone Health - August 3rd, 2022
- Do ICDs Still Work in Primary Prevention Given Today's HF Meds? - Medscape - August 3rd, 2022
- Alzheimer's-defying brain offers clues to treatment, prevention - Harvard Gazette - August 3rd, 2022
- Wind-fanned lightning fire prompted precautionary evacuation notices near Medical Springs Sunday evening - Baker City Herald - August 3rd, 2022
- Experts discuss importance of cancer screenings and early detection - Merck - August 3rd, 2022
- King Institute of Preventive Medicine and Research to test samples for monkeypox - The Hindu - August 3rd, 2022
- Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations - World - ReliefWeb - August 3rd, 2022
- Dr. Sanjay Gupta: While monkeypox cases rise, why are we waiting for the cavalry to rescue us? - CNN - August 3rd, 2022
- SCYNEXIS Announces U.S. Food and Drug Administration - GlobeNewswire - August 3rd, 2022
- Governor Whitmer declares August 2022 as Breastfeeding Month, highlights additional breastfeeding observances - Michigan (.gov) - August 3rd, 2022
- New student education program supports drug and alcohol abuse prevention - The Ohio State University News - July 25th, 2022
- Suicide prevention training for health care providers a first step in longer-term efficacy - University of Washington - July 25th, 2022
- Pharmalittle: Congress may miss deadline to pass FDA user-fee bill; ViiV is urged to lower price for its HIV prevention drug - STAT - July 25th, 2022
- Prevention of Bipolar Disorder Episodes: Is It Possible? - PsychCentral.com - July 25th, 2022
- GAO Found Gap in Dirty Bomb Prevention - Government Technology - July 25th, 2022
- Florida man in apparent medical distress crashes car through beach crowd before hitting the water - CNN - July 25th, 2022
- Study: Preventive care scarce in LGBTQ+ community - - Medical Marketing and Media - July 25th, 2022
- The rise of preventive insurance purchases in India - ETHealthWorld - July 25th, 2022
- Why Are My Feet Always Cold? Cold Feet Causes and Treatment - Prevention Magazine - July 25th, 2022
- Agency looking to open overdose prevention site in Saint John amid 'poisoned' drug supply - CBC.ca - July 25th, 2022
- UVA Expert Offers Insight on the Use of Dietary Supplements for Cancer Prevention - UVA Today - July 25th, 2022
- Alzheimer's: Targeting key protein in blood may slow progression - Medical News Today - July 25th, 2022
- NPPC, FAS focused on ASF prevention in the Philippines - MEAT+POULTRY - July 25th, 2022
- Implementation of IPT in people living with HIV | RMHP - Dove Medical Press - July 25th, 2022
- NL starts preventive vaccination against monkeypox in Amsterdam, The Hague - NL Times - July 25th, 2022
- Precautionary measures you can take against brain haemorrhage - Times of India - July 25th, 2022
- Acid Reflux and Liver Disease: Signs, Symptoms and Prevention - Healthline - July 25th, 2022
- What to do if you get an allergic reaction: symptoms, causes, and prevention - Fox News - July 25th, 2022
- How one woman took control of her rare disease and achieved her dream - Times of Oman - July 25th, 2022
- Tilman Fertitta donating $50 million to UH medical school, which will be renamed after him - Houston Chronicle - May 20th, 2022
- This new 3D screensaver collection includes a driving tour of global pylons - Rock Paper Shotgun - May 20th, 2022
- Dedication, generosity and compassion that had no limit! - The Sun Chronicle - May 20th, 2022
- Manhattan internist and cardiologist, Dr. William Priester collaborates with Castle Connolly Private Health Partners to create a new concierge medical... - May 20th, 2022
- Tips on avoiding mosquitos this summer - morethanthecurve.com - May 20th, 2022
- Nanomedicine and HIV Therapeutics - AZoNano - May 20th, 2022
- The HIV Vaccine: What We Know, And What We Don't - MadameNoire - May 20th, 2022
- What we know (and don't know) about North Korea's COVID-19 outbreak - WCVB Boston - May 20th, 2022
- Experts warn of health effects from dusty conditions as sandstorm blankets UAE - Al Arabiya English - May 20th, 2022
- Statin therapy: Does the gut microbiome affect outcomes? - Medical News Today - May 20th, 2022
- New Preventative Medicine Facility Wraps Work in NYC - Healthcare Construction and Operations News - November 7th, 2021
- MPD working with faith-based leaders to fight violent crime - FOX13 Memphis - November 7th, 2021
- Cornell grad and lecturer touts benefits of plant-based diet - ithaca.com - November 7th, 2021
- Meet the Cork-born bread activist who has Goldie Hawn buying her loaves - Irish Examiner - November 7th, 2021
- Pfizer says pill cuts risk of severe Covid by 89% - RTE.ie - November 7th, 2021
- The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm - Yahoo News - November 7th, 2021